Asahi Kasei launches Phase III trial of Teribone (teriparatide acetate) in Japan
- Asahi Kasei Therapeutics has started a domestic Phase III trial of Teribone (teriparatide acetate) in Japan.
- The trial targets patients at high fracture risk who have completed 24 months of teriparatide treatment and still require therapy.
- Teribone dosing in the trial is once weekly 56.5 μg or twice weekly 28.2 μg.
- Trial registry ID is jRCT2031260049.
Trial objective
Asahi Kasei Therapeutics has initiated a domestic Phase III clinical trial in Japan to evaluate the efficacy and safety of continued Teribone (teriparatide acetate) administration in patients with osteoporosis at high risk of fracture who have already completed 24 months of teriparatide treatment and continue to demonstrate a clinical need.
Drug and dosing
Teribone is a human parathyroid hormone (PTH) preparation intended to promote bone formation, increase bone mass and reduce fracture risk. In clinical use it is administered either once per week (56.5 μg) or twice per week (28.2 μg).
Clinical context
Non‑clinical findings currently limit teriparatide preparations to a maximum treatment duration of 24 months in Japan. This cap creates a challenge for patients who require extended bone‑forming therapy, and the Phase III trial is designed to generate evidence on prolonged administration for those continuing to need treatment.
Remarks and trial registry
Daisuke Okajima, President of Asahi Kasei Therapeutics, said the trial is an important step toward prolonged Teribone administration for patients at high risk of fracture. Trial ID: jRCT2031260049.
Source: Asahi Kasei
